Bevacizumab Biosimilars

November 2, 2022

Dear OMIC Insureds:

An increasing number of ophthalmologists treating retinal conditions with intravitreal anti-VEGF agents are being asked by health systems and hospitals to utilize bevacizumab biosimilar drugs. Both the AAO (2022) and CMS (2021) have issued statements recommending against the use of off-label bevacizumab biosimilars to treat ocular conditions due to insufficient data regarding long-term efficacy and safety profiles. OMIC supports these statements and strongly recommends against the use of bevacizumab biosimilar drugs for intravitreal injection, as well as off-label use of all biosimilars for the treatment of ROP until further clinical data becomes available.

If you have questions about this topic or would like to have a confidential risk management consultation, please email riskmanagement@omic.com or 1-800-562-6642, enter 4 for OMIC Risk Management.

Sincerely,

Michael C. Tigani, MD
Chair, OMIC Risk Management Committee

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Six reasons OMIC is the best choice for ophthalmologists in America.

Best at defending claims.

An ophthalmologist pays nearly half a million dollars in premiums over the course of a career. Premium paid is directly related to a carrier’s claims experience. OMIC has a higher win rate taking tough cases to trial, full consent to settle (no hammer) clause, and access to the best experts. OMIC pays 25% less per claim than other carriers. As a result, OMIC has consistently maintained lower base rates than multispecialty carriers in the U.S.

Risk Management

Bevacizumab Biosimilars